vTv Therapeutics Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul J. Sekhri
- Full Time Employees
- 26
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3980 Premier Drive High Point NC United States of America 27265
- IPO Date
- Jul 30, 2015
- CIK
- 0001641489
- Website
- vtvtherapeutics.com
- Similar Companies
- Business
- vTv Therapeutics Inc. vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company incorporated in 2015 and headquartered in High Point, North Carolina, focuses on the discovery, development and commercialization of orally administered small molecule drug candidates for metabolic diseases, particularly diabetes, inflammatory conditions and other chronic disorders. The company operates primarily in the United States with global partnerships for certain territories and serves patient populations with type 1 diabetes, cystic fibrosis-related diabetes, type 2 diabetes, psoriasis, COPD, atopic dermatitis, primary mitochondrial myopathy and oxidative stress-related diseases. Its lead product candidate, cadisegliatin (TTP399), comprises a liver-selective glucokinase activator in Phase 3 clinical trials as an adjunctive therapy to insulin for type 1 diabetes to reduce hypoglycemic events; TTP273 functions as a glucagon-like peptide 1 receptor agonist in Phase 1 for cystic fibrosis-related diabetes postprandial hyperglycemia and Phase 2 for type 2 diabetes; HPP737 serves as a non-CNS penetrant PDE4 inhibitor that completed Phase 1 trials for psoriasis, COPD and atopic dermatitis; HPP593 acts as a PPAR-delta activator for primary mitochondrial myopathy; HPP3033 targets the Nrf2 pathway for oxidative stress-associated chronic diseases; azeliragon targets RAGE for pancreatic cancer; and additional programs address renal diseases, T1D prevention and undisclosed indications. vTv Therapeutics maintains worldwide rights to TTP399 and HPP3033 while partnering with entities such as Newsoara Biopharma for HPP737 in China and the Pacific Rim excluding Japan, Huadong Medicine for TTP273 in similar regions, Reneo Pharmaceuticals for HPP593 worldwide with retained equity interest, Anteris Bio for HPP971 in renal diseases with equity interest, and Cantex for azeliragon worldwide. As a majority-owned subsidiary of MacAndrews & Forbes Group LLC, the company recently completed an $80 million private placement in September 2025 with new and existing investors including Samsara BioCapital, T1D Fund, Trails Edge Capital Partners and Invus to fund the ongoing Phase 3 CATT1 trial for cadisegliatin and pipeline advancement; terminated its licensing agreement with OnKure Therapeutics (formerly Reneo Pharmaceuticals) effective January 2025 for the PPAR-delta agonist program; secured prior investments such as $51 million in early 2025 and $10 million from CinRx Pharma in 2022; advanced cadisegliatin with FDA Breakthrough Therapy designation, Phase 2b data and Phase 3 initiation; and reported $98.5 million in cash as of September 30, 2025 following the financing.
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics to Participate in Upcoming May Investor Conferences
Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst
vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 61.2% in February
vTv Therapeutics to Participate in Upcoming Investor Conferences
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
Does vTv Therapeutics (VTVT) Have the Potential to Rally 25.17% as Wall Street Analysts Expect?
All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy